Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Covalon Technologies Ltd. (V:COV)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 1660 Tech Avenue, Unit 5
MISSISSAUGA ON L4W 5S7
Tel: 1-877-7116055
Website: https://covalon.com
IR: See website
Key People
Amir Boloor
Executive Chairman of the Board
Brent Ashton
Chief Executive Officer, Director
Katie Martinovich
Interim Chief Financial Officer
Ronald Hebert
Senior Vice President - Marketing
Kim Crooks
Senior Vice President - Operations
Jason F. Gorel
Vice President - Finance
Business Overview
Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.
Financial Overview
For the three months ended 31 December 2023, Covalon Technologies Ltd revenues decreased 25% to C$4.7M. Net loss increased from C$381K to C$852K. Revenues reflect Middle East segment decrease of 72% to C$379K, Rest of World segment decrease of 85% to C$136K, Middle East (Region) segment decrease of 72% to C$379K, Rest of World segment decrease of 85% to C$136K.
Reporting Currency: Canadian Dollars
Enterprise value: $21.60M as of Dec 31, 2023
Annual revenue (TTM): $25.07M as of Dec 31, 2023
EBITDA (TTM): -$4.68M as of Dec 31, 2023
Net annual income (TTM): -$4.93M as of Dec 31, 2023
Free cash flow (TTM): -$3.82M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,669,577 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization